ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms
Peer-Reviewed Publication
This month, we're turning our attention to Breast Cancer Awareness Month, a time dedicated to increasing awareness, supporting early detection, and highlighting the ongoing research shaping the future of breast cancer treatment and prevention.
Updates every hour. Last Updated: 20-Oct-2026 08:16 ET (20-Oct-2026 12:16 GMT/UTC)
One of the major challenges in the treatment of the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance. In new research published today in Science Advances, Boston Children’s Hospital researchers and colleagues have discovered a new driver of resistance in this cancer, introducing a new direction for early diagnosis of the resistant cancer cells, and a possible path to target them.
Despite cancer rates similar to Western Europe, patients in the Balkans are far more likely to die from the disease. Experts point to delayed detection, weak primary care, and limited access to advanced diagnostics as the principal culprits.
Across the Balkan Peninsula, health systems face a stark contradiction: while the incidence of solid tumours broadly mirrors that of Western Europe, mortality remains stubbornly elevated. Lung, colorectal, and prostate cancers are the leading killers among men, while breast, lung, colorectal, and cervical cancers take the heaviest toll on women.
New treatments – including experimental cancer vaccines from Moderna show promise in late-stage trials, but their cost puts them out of reach for most patients in the region. According to Dr Marchela Koleva, founder and Head of the Department of Medical Oncology at St. Sophia Hospital the core problem is not a lack of therapies but a chronic failure to diagnose early enough.